Related Experiment Videos
Immunoglobulin binding factor: a new tumor marker for prostatic tumors
1Department of Obstetrics and Gynecology, School of Medicine, University of Tokushima, Japan.
The Prostate
|January 1, 1994
Summary
Immunoglobulin gamma binding factor (IgBF), found in seminal plasma and prostate tissue, shows elevated serum levels in patients with prostate cancer. This suggests IgBF may serve as a novel biomarker for diagnosing prostate tumors.
Area of Science:
- Urology
- Biochemistry
- Oncology
Background:
- Human seminal plasma contains an immunoglobulin gamma binding factor (IgBF), a 16 kD protein.
- IgBF is specifically detected in prostate tissue, including cases of benign prostatic hypertrophy (BPH) and neoplasm.
Purpose of the Study:
- To investigate the potential of IgBF as a diagnostic marker for prostatic diseases.
- To compare serum IgBF levels with established markers like prostate-specific antigen (PSA).
Main Methods:
- Serum IgBF levels were quantified using radioimmunoassay in patients with prostate tumors and age-matched controls.
- Serum PSA levels were also measured as a standard prostatic marker.
Main Results:
- Serum IgBF levels were significantly higher in prostate cancer patients compared to controls (P < 0.05).
- Elevated IgBF levels were observed in BPH patients, though not statistically significant.
- Serum IgBF levels increased with age in control individuals.
- No correlation was found between serum IgBF and PSA levels in prostate cancer patients.
Conclusions:
- Serum IgBF demonstrates potential as a useful biomarker for diagnosing prostatic tumors.
- IgBF may aid in monitoring treatment efficacy for patients with prostate cancer.